Aldosterone receptor antagonists for heart failure: Current status, future indications
Cleveland Clinic Journal of Medicine. 2006 March;73(3):257-260, 264-268
March 1, 2006|Cleveland Clinic Journal of Medicine
Author and Disclosure Information
ABSTRACTMany patients with heart failure should receive an aldosterone receptor antagonist, ie, either spironolactone (Aldactone) or the newer agent eplerenone (Inspra)—in addition to an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB) or both, and a beta-blocker. We review the evidence and indications.
